Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
MJ Grant, RS Herbst, SB Goldberg - Nature reviews Clinical oncology, 2021 - nature.com
The treatment landscape of driver-negative non-small-cell lung cancer (NSCLC) is rapidly
evolving. Immune-checkpoint inhibitors, specifically those targeting PD-1 or PD-L1, have …
evolving. Immune-checkpoint inhibitors, specifically those targeting PD-1 or PD-L1, have …
RET signaling pathway and RET inhibitors in human cancer
AT Regua, M Najjar, HW Lo - Frontiers in oncology, 2022 - frontiersin.org
Rearranged during transfection (RET) receptor tyrosine kinase was first identified over thirty
years ago as a novel transforming gene. Since its discovery and subsequent pathway …
years ago as a novel transforming gene. Since its discovery and subsequent pathway …
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
Background Oncogenic alterations in RET have been identified in multiple tumour types,
including 1–2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety …
including 1–2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety …
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 …
SB Goldberg, KA Schalper, SN Gettinger… - The Lancet …, 2020 - thelancet.com
Background We did a phase 2 trial of pembrolizumab in patients with non-small-cell lung
cancer (NSCLC) or melanoma with untreated brain metastases to determine the activity of …
cancer (NSCLC) or melanoma with untreated brain metastases to determine the activity of …
Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial
PURPOSE Insertion mutations in Erb-b2 receptor tyrosine kinase 2 gene (ERBB2 or HER2)
exon 20 occur in 2%-5% of non–small-cell lung cancers (NSCLCs) and function as an …
exon 20 occur in 2%-5% of non–small-cell lung cancers (NSCLCs) and function as an …
[HTML][HTML] First-line nivolumab plus ipilimumab with chemotherapy versus chemotherapy alone for metastatic NSCLC in CheckMate 9LA: 3-year clinical update and …
Abstract Introduction In the phase 3 CheckMate 9LA study, nivolumab plus ipilimumab with
chemotherapy prolonged overall survival (OS) versus chemotherapy alone. We report …
chemotherapy prolonged overall survival (OS) versus chemotherapy alone. We report …
[HTML][HTML] Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic NSCLC and baseline brain metastases from …
M Reck, TE Ciuleanu, JS Lee, M Schenker… - Journal of Thoracic …, 2023 - Elsevier
Abstract Introduction In CheckMate 227 Part 1, nivolumab plus ipilimumab prolonged overall
survival (OS) versus chemotherapy in patients with metastatic NSCLC, regardless of tumor …
survival (OS) versus chemotherapy in patients with metastatic NSCLC, regardless of tumor …
Phase II trial of atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non–small-cell lung cancer with untreated brain …
PURPOSE The Atezo-Brain study evaluated atezolizumab combined with chemotherapy in
patients with advanced non–small-cell lung cancer (NSCLC) with untreated brain …
patients with advanced non–small-cell lung cancer (NSCLC) with untreated brain …
Single-cell transcriptomic analyses provide insights into the cellular origins and drivers of brain metastasis from lung adenocarcinoma
Z Wang, Y Wang, M Chang, Y Wang, P Liu… - Neuro …, 2023 - academic.oup.com
Background Brain metastasis (BM) is the most common intracranial malignancy causing
significant mortality, and lung cancer is the most common origin of BM. However, the cellular …
significant mortality, and lung cancer is the most common origin of BM. However, the cellular …
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
C Zhou, Z Wang, M Sun, L Cao, Z Ma, R Wu, Y Yu… - Nature cancer, 2023 - nature.com
The randomized, double-blinded, multi-center, phase III GEMSTONE-302 (NCT03789604)
study evaluated the efficacy and safety of sugemalimab versus placebo in combination with …
study evaluated the efficacy and safety of sugemalimab versus placebo in combination with …